SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) completed its public debut through a merger with Big Rock Partners Acquisition Corp, a blank-check company sponsored by Big Rock Partners LLC that raised capital in its January 2021 IPO via a 424B4 prospectus filed with the SEC on January 12, 2021. The business combination closed in late 2021, bringing SAB Biotherapeutics — a clinical-stage biopharmaceutical company focused on developing human polyclonal antibodies through its proprietary DiversitAb platform using genetically engineered cattle — into the public markets under the SABS ticker. The company operates in the healthcare and biopharmaceutical sector, targeting infectious diseases and other serious conditions. Visit SpacDesk and sign up for full data, filings, and deal analytics on SABS and hundreds of other SPAC transactions.